Log in

Relevant bibliographies by topics / Adjuvant chemoradiation / Journal articles

To see the other types of publications on this topic, follow the link: Adjuvant chemoradiation.

Journal articles on the topic 'Adjuvant chemoradiation'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Adjuvant chemoradiation.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

van Kol, Kim, Renée Ebisch, Jurgen Piek, Maaike Beugeling, Tineke Vergeldt, and Ruud Bekkers. "Adjuvant Hysterectomy for Cervical Cancer Patients Treated with Chemoradiation Therapy: A Systematic Review on the Pathology-Proven Residual Disease Rate." Cancers 13, no. 24 (2021): 6190. http://dx.doi.org/10.3390/cancers13246190.

Full text

Abstract:

Objective: To determine the incidence of pathology-proven residual disease in adjuvant hysterectomy specimens in patients with cervical cancer, treated with chemoradiation therapy. Secondly, to assess a possible association for pathology-proven residual disease regarding the time between chemoradiation therapy and adjuvant hysterectomy. Additionally, the survival rate and complication rate were assessed. Methods: PubMed, EMBASE, and the Cochrane database were searched from inception up to 8 March 2021. Results: Of the 4601 screened articles, eleven studies were included. A total of 1205 patien

APA, Harvard, Vancouver, ISO, and other styles

2

Markelis, Rytis, Žilvinas Endzinas, Mindaugas Kiudelis, et al. "Adjuvant therapy after curative resection with D2 lymphadenectomy for gastric cancer: Results of a prospective clinical trial." Medicina 45, no. 6 (2009): 460. http://dx.doi.org/10.3390/medicina45060060.

Full text

Abstract:

Objective. Adjuvant chemoradiation for gastric cancer is used more frequently, but there is no general opinion about the effect of this treatment. The aim of this study was to compare adjuvant chemoradiation with adjuvant chemotherapy after radical operation for stomach cancer. Material and methods. A total of 133 patients were included in this prospective study. Sixty-three patients after curative gastrectomy and D2 lymphadenectomy for gastric cancer were assigned to the chemoradiotherapy group and 70 to the chemotherapy group. The groups were identical by age, sex, and cancer stages. Toxicit

APA, Harvard, Vancouver, ISO, and other styles

3

Mayer. "Efficacy of Neo- and Adjuvant Treatment Modalities in Gastrointestinal Cancer Patients." Swiss Surgery 7, no. 6 (2001): 239–42. http://dx.doi.org/10.1024/1023-9332.7.6.239.

Full text

Abstract:

Data which have emerged from randomized clinical trials are inconclusive regarding the efficacy of neoadjuvant chemoradiation therapy for patients with esophageal cancer. In 2001, available data appear to support the use of adjuvant chemoradiation therapy following the complete resection of a gastric cancer, adjuvant chemotherapy following the resection of a stage III (and - probably - "high-risk" stage II) colon cancer, and the use of adjuvant (and most likely neoadjuvant) chemoradiation therapy for stages II and III rectal cancer.

APA, Harvard, Vancouver, ISO, and other styles

4

Chen, Yongshun, Daxuan Hao, Xiaoyuan Wu, et al. "Neoadjuvant or adjuvant chemoradiation therapy for stage II-III esophageal squamous cell carcinoma." Journal of Clinical Oncology 33, no. 3_suppl (2015): 202. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.202.

Full text

Abstract:

202 Background: Esophageal cancer is the eighth most common cancer worldwide, and especially in China is the fourth most common cause of death. Clinical trials have explored the value of neoadjuvant or adjuvant chemoradiation in potentially resectable esophageal squamous cell carcinoma (ESCC); however, these studies have produced conflicting results. This retrospective study was performed to investigate whether patients with resectable stage II/III ESCC should receive neoadjuvant or adjuvant therapy in addition to surgery. Methods: A review of stage II/III ESCC patients who underwent esophagec

APA, Harvard, Vancouver, ISO, and other styles

5

Seaton, Max, Andrew Hanna, Cherif Boutros, and Nader Hanna. "Adjuvant therapy for pancreatic body or tail adenocarcinoma: a study of the National Cancer Database." Therapeutic Advances in Medical Oncology 11 (January 2019): 175883591984243. http://dx.doi.org/10.1177/1758835919842438.

Full text

Abstract:

Background: The optimal multimodality therapy for pancreatic ductal adenocarcinoma in the body or tail of the pancreas (PDAC-BT) is unclear. The purpose of this study was to compare overall 5-year survival between patients treated with adjuvant chemotherapy, adjuvant chemoradiation, and surgery alone. Methods: Patients from the National Cancer Database (1998–2012) with resected stage I or II PDAC-BT were included. Overall survival between the three treatment groups was compared using Cox proportional-hazards regression, propensity-score matching, and the Kaplan–Meier method. Results: Of the 70

APA, Harvard, Vancouver, ISO, and other styles

6

Ahmed, Aabra, Ryan W. Walters, Timothy Dean Malouff, Mridula Krishnan, Javaneh Jabbari, and Peter T. Silberstein. "Adjuvant therapy in stage II pancreatic cancer: A National Cancer Database analysis." Journal of Clinical Oncology 35, no. 4_suppl (2017): 283. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.283.

Full text

Abstract:

283 Background: Oldfield et al (2015) showed the conflicting evidence regarding the effect of adjuvant chemotherapy vs. chemoradiation in pancreatic cancer. Using patients identified by the National Cancer Database (NCDB), we are the largest study to compare survival in stage II pancreatic cancer patients who received adjuvant chemotherapy, chemoradiation, radiation, or no adjuvant therapy. Methods: We identified 65,091 patients with stage II pancreatic cancer who received surgery only or surgery in combination with chemotherapy, radiation, or chemoradiation. Between-therapy survival differenc

APA, Harvard, Vancouver, ISO, and other styles

7

Alkış, Hilal, Rukiye Arıkan, Aleksei Kornienko, Hatice Kübra Gündüz, and Mustafa Adlı. "Timing of adjuvant chemoradiation for pancreatic cancer with positive surgical margins." Journal of Translational and Practical Medicine 2, no. 2 (2023): 60–63. http://dx.doi.org/10.51271/jtpm-0042.

Full text

Abstract:

Aims: Impact of adjuvant chemoradiation timing on the outcome of pancreatic cancer patients with positive surgical margins is unknown. The aim of this study was to evaluate the effect of adjuvant chemoradiation timing for margin positive pancreatic cancer patients. Methods: A total of 36 pancreatic adenocarcinoma patients with positive surgical margins and received adjuvant chemoradiation were included in the study. The median radiation dose was 50.4 Gy in 28 fractions. The primary study variable was the timing of chemoradiation, grouped as immediate (after ? 1 cycle of chemotherapy) and delay

APA, Harvard, Vancouver, ISO, and other styles

8

Ali, Nasir, Azmina Tajdin Valimohammad, Ahmed Nadeem Abbasi, Muhammad Atif Mansha, Asim Hafiz, and Bilal Mazhar Qureshi. "Chemoradiation and the Role of Adjuvant Chemotherapy in Lymph Nodal–Metastatic Cervical Cancer." Journal of Global Oncology, no. 4 (December 2018): 1–4. http://dx.doi.org/10.1200/jgo.2017.009852.

Full text

Abstract:

Purpose To report the long-term outcome in lymph nodal–metastatic cervical squamous cell cancer after chemoradiation followed by adjuvant chemotherapy. Patients and Methods Between 2010 and 2013, five patients were diagnosed with advanced cervical cancer with clinically involved para-aortic lymph nodes (ie, International Federation of Gynecology and Obstetrics stage IVB). These patients were treated with concurrent chemoradiation therapy followed by adjuvant chemotherapy. Concurrent chemoradiation consisted of cisplatin given once per week concomitantly with extended-field radiation therapy fo

APA, Harvard, Vancouver, ISO, and other styles

9

Phillips, John G., Theodore S. Hong, and David P. Ryan. "Multidisciplinary Management of Early-Stage Rectal Cancer." Journal of the National Comprehensive Cancer Network 10, no. 12 (2012): 1577–85. http://dx.doi.org/10.6004/jnccn.2012.0160.

Full text

Abstract:

Because patients with locally advanced rectal cancer are at high risk for both recurrence and distant disease, they require adjuvant therapy. In the United States, the current standard of care is neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy. Neoadjuvant chemoradiation has been shown to improve local recurrence rates and decrease toxicity. However in the era of total mesorectal excision surgery, no study has shown a survival benefit to either chemoradiation or postoperative chemotherapy. Newer biologic therapies, although promising in initial early trials, have yet t

APA, Harvard, Vancouver, ISO, and other styles

10

Lv, Jiahua, Tao Li, Qifeng Wang, et al. "Neoadjuvant versus adjuvant chemoradiotherapy for stage II–III esophageal squamous cell carcinoma: A propensity score-matched analysis." Journal of Clinical Oncology 37, no. 15_suppl (2019): e15524-e15524. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e15524.

Full text

Abstract:

e15524 Background: Many clinical trials have explored the value of neoadjuvant or adjuvant chemoradiation therapy in stage II–III squamous cell carcinoma (ESCC). However, these studies have produced conflicting results. This retrospective study was performed to investigate whether patients with stage II/III ESCC should receive neoadjuvant or adjuvant therapy in addition to surgery. Methods: A total of 206 patients with clinical stage II and III ESCC who underwent esophagectomy and either neoadjuvant or adjuvant chemoradiation were included. On the basis of the sequence of surgery and chemoradi

APA, Harvard, Vancouver, ISO, and other styles

11

Kumar, Aryavarta M. S., Gavin Falk, Kevin L. Stephans, Matthew Walsh, Robert James Pelley, and May Abdel-Wahab. "Adjuvant chemoradiation to improve survival compared to adjuvant chemotherapy in selected patients with pancreatic cancer." Journal of Clinical Oncology 32, no. 3_suppl (2014): 330. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.330.

Full text

Abstract:

330 Background: While surgery remains the only potential curative option for resectable pancreatic cancer, adjuvant therapy improves outcomes over surgery alone; however, adjuvant recommendations of chemotherapy vs chemoradiation remain controversial. We present outcomes comparing the two adjuvant treatments. Methods: In our single institution review, 343 patients (2000-2012) had pancreatoduodenectomy for pancreatic cancer. Medical oncology made adjuvant recommendations. Chemotherapy was gemcitabine or 5-FU and radiotherapy prescription was 45-54 Gy. Locoregional recurrences (LRR) were operati

APA, Harvard, Vancouver, ISO, and other styles

12

Wong, L. C., H. Y. S. Ngan, A. N. Y. Cheung, D. K. L. Cheng, T. Y. Ng, and D. T. K. Choy. "Chemoradiation and Adjuvant Chemotherapy in Cervical Cancer." Journal of Clinical Oncology 17, no. 7 (1999): 2055. http://dx.doi.org/10.1200/jco.1999.17.7.2055.

Full text

Abstract:

PURPOSE: Radiotherapy is the standard treatment for locally advanced cervical cancer, but treatment results remain disappointing, particularly for women with bulky central disease. We investigated the role of concurrent chemoradiation and adjuvant chemotherapy in a randomized trial. PATIENTS AND METHODS: Two hundred twenty patients with bulky stage I, II, and III cervical cancer were randomized to receive either standard pelvic radiotherapy or chemoradiation (epirubicin 60 mg/m2) followed by adjuvant chemotherapy with epirubicin 90 mg/m2 administered at 4-week intervals for five additional cyc

APA, Harvard, Vancouver, ISO, and other styles

13

Hadzitheodorou, Christina, Rebecca A. Moss, Timothy J. Kennedy, and Salma K. Jabbour. "Neoadjuvant Chemotherapy and Adjuvant Chemoradiation Therapy in the Treatment of Resected Gastric Adenocarcinoma: A Case Series." Case Reports in Oncology 10, no. 1 (2017): 308–15. http://dx.doi.org/10.1159/000464280.

Full text

Abstract:

The treatment of gastric cancer requires a multimodal approach to decrease the risk of locoregional and distant recurrence. The optimal timing of chemotherapy, surgery, and radiation therapy continues to be explored in ongoing trials. In the United States, surgical resection is often followed by adjuvant chemoradiation therapy or by a combination of neoadjuvant and adjuvant chemotherapy. Here we report on 4 patients with resected gastric adenocarcinoma who were treated with a combination of these 2 approaches, receiving neoadjuvant chemotherapy followed by adjuvant chemoradiation therapy.

APA, Harvard, Vancouver, ISO, and other styles

14

Kuang, Ming, Zhenwei Peng, Shun-Li Shen, Shuling Chen, and Han Xiao. "Adjuvant chemoradiation combined with immunotherapy for patients with high-risk resectable extrahepatic cholangiocarcinoma and gallbladder cancer: A phase II, multicenter, randomized controlled trial (ACCORD trial)." Journal of Clinical Oncology 43, no. 4_suppl (2025): 570. https://doi.org/10.1200/jco.2025.43.4_suppl.570.

Full text

Abstract:

570 Background: Extrahepatic cholangiocarcinoma (ECC) and gallbladder cancer (GBC), as the majority of biliary tract cancer (BTC), has a markedly high risk of recurrence after surgery. However, adjuvant treatments specifically for resectable ECC and GBC patients are scare and adjuvant chemotherapy alone delivers limited efficacy. Immunotherapy and radiotherapy are potential effective treatments and both of them may synergize with chemotherapy. Methods: ACCORD was a multicenter, phase 2, randomized controlled trial to assess the efficacy and safety of chemoradiation with immunotherapy as an adj

APA, Harvard, Vancouver, ISO, and other styles

15

Muller, B. G., J. A. Sola, M. Carcamo, A. Sola, A. M. Ciudad, and C. Trujillo. "Adjuvant chemoradiation for resected gallbladder cancer." Journal of Clinical Oncology 29, no. 4_suppl (2011): 319. http://dx.doi.org/10.1200/jco.2011.29.4_suppl.319.

Full text

Abstract:

319 Background: Gallbladder cancer (GBC) is the leading cause of cancer death in women in Chile. Even after curative surgery, prognosis is grim. To evaluate acute and late toxicity and efficacy in terms of overall survival of adjuvant chemoradiation (CR) after curative resection of GBC. Methods: We retrospectively analyzed the cohort of patients with curatively resected GBC diagnosed between January 1999 and April 2009, treated with adjuvant CR at the Instituto Nacional del Cáncer, Santiago de Chile. Treatment protocol considered external beam radiation therapy (RT) (45–54 Gy) to tumor bed and

APA, Harvard, Vancouver, ISO, and other styles

16

Cho, Seong Yeon, Seong Hoon Kim, Sang-Jae Park, et al. "Adjuvant chemoradiation therapy in gallbladder cancer." Journal of Surgical Oncology 102, no. 1 (2010): 87–93. http://dx.doi.org/10.1002/jso.21544.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Zhang, Qing, Jeremy Tey, Zhe Yang, et al. "Adjuvant Chemoradiation Plus Intraoperative Radiotherapy Versus Adjuvant Chemoradiation Alone in Patients With Locally Advanced Rectal Cancer." American Journal of Clinical Oncology 38, no. 1 (2015): 11–16. http://dx.doi.org/10.1097/coc.0b013e318287bb8d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Horeweg, Nanda, Prachi Mittal, Patrycja L. Gradowska, Ingrid Boere, Supriya Chopra, and Remi A. Nout. "Adjuvant Systemic Therapy after Chemoradiation and Brachytherapy for Locally Advanced Cervical Cancer: A Systematic Review and Meta-Analysis." Cancers 13, no. 8 (2021): 1880. http://dx.doi.org/10.3390/cancers13081880.

Full text

Abstract:

Background: Standard of care for locally advanced cervical cancer is chemoradiation and brachytherapy. The addition of adjuvant systemic treatment may improve overall survival. A systematic review and meta-analysis was conducted to summarize evidence on survival outcomes, treatment completion and toxicity. Methods: PubMed, EMBASE and Web of Science were systematically searched for relevant prospective and retrospective studies. Two authors independently selected studies, extracted data and assessed study quality. Pooled hazard ratios for survival endpoints were estimated using random effect mo

APA, Harvard, Vancouver, ISO, and other styles

19

Deem, Jennifer D., Zsolt Hepp, and Joshua J. Carlson. "Real-World Treatment Patterns and Outcomes Among Patients with Early Non-Small Cell Lung Cancer." Current Oncology 32, no. 4 (2025): 239. https://doi.org/10.3390/curroncol32040239.

Full text

Abstract:

Worldwide, about two million people are diagnosed with lung cancer each year, 85% of whom have non-small cell lung cancer (NSCLC). Recent progress in treating advanced/metastatic NSCLC with targeted therapies has shifted attention to early NSCLC (Stages I–IIIA) and perioperative (neoadjuvant and adjuvant) systemic therapies. However, our comprehension of how targeted therapeutics are incorporated into care and their impact on patient outcomes is just starting to unfold. Methods: This retrospective observational study used a US nationwide electronic health record-derived deidentified database s

APA, Harvard, Vancouver, ISO, and other styles

20

Smaglo, Brandon George, Yvonne Sada, Hop Sanderson Tran Cao, et al. "Pathologic nodal response in gastric cancer: Do all patients need adjuvant therapy?" Journal of Clinical Oncology 35, no. 4_suppl (2017): 107. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.107.

Full text

Abstract:

107 Background: Recent data from the MAGIC trial show that pathologically positive lymph nodes (ypN+) despite neoadjuvant (NA) chemotherapy are associated with poorer survival. Although the use of NA therapy has increased, pathologic disease response to multimodality therapy (MMT) and its impact on outcome have not been well-defined. Methods: This retrospective cohort study of the National Cancer Database included patients with cN+ gastric cancer who underwent NA therapy followed by surgical resection between 2006 and 2012. Patients were categorized by NA treatment (chemotherapy or concurrent

APA, Harvard, Vancouver, ISO, and other styles

21

Shah, Anish, Lakshmi Bhavani Potluri, Pravash Budhathoki, Suman Gaire, and Dipesh Uprety. "Surgery with adjuvant chemotherapy versus chemoradiation for early-stage large cell neuroendocrine cancer (LCNEC) of the lung: A SEER plus based analysis." Journal of Clinical Oncology 41, no. 16_suppl (2023): e20616-e20616. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e20616.

Full text

Abstract:

e20616 Background: LCNEC of the lung is a rare and highly aggressive tumor with neuroendocrine differentiation. Given its rare occurrence and lack of data from large randomized trials, treatment recommendations are based on the extrapolation of data, primarily from small-cell lung cancer studies. We conducted this study to evaluate the survival difference among patients with LCNEC with an N1 disease between those who received surgery and adjuvant chemotherapy versus definitive chemotherapy and radiotherapy. Methods: We utilized Surveillance, Epidemiology, and End Results (SEER) plus 18 registr

APA, Harvard, Vancouver, ISO, and other styles

22

Sharma, Jyoti, Manish Gupta, Siddharth Vats, and Naina Negi. "Can definitive chemoradiation offer a cure along with cosmesis in locally advanced IVA carcinoma buccal mucosa? a case report." International Journal of Clinical Trials 10, no. 3 (2023): 263–65. http://dx.doi.org/10.18203/2349-3259.ijct20232201.

Full text

Abstract:

Surgery is the mainstay of the treatment in ca buccal mucosa. It is extensive in nature and may require efficient reconstruction for good cosmetic outcome. Adjuvant radiation or chemo-radiation may be needed in advanced cancers. Definitive chemoradiation or palliative radiation are reserved for inoperable patients. We present a case report of advanced carcinoma of oral cavity in the left buccal mucosa along with involvement of retromolar trigone along with bone involvement in left sided mandible who opted out for undergoing definitive surgery. She was treated with definitive chemoradiation wit

APA, Harvard, Vancouver, ISO, and other styles

23

Samuel, Maya Mary, Prachi Saldhi, Peter T. Silberstein, and Jasleen Kaur Chaddha. "Analyzing the effect of treatment modalities on survival in synovial sarcoma." Journal of Clinical Oncology 42, no. 16_suppl (2024): 11570. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.11570.

Full text

Abstract:

11570 Background: Synovial sarcoma (SS) is a rare, slow growing, and aggressive soft tissue sarcoma that commonly affects young adults, with a diagnosis at an average age of 30 years. It usually originates near the joints of the extremities and presents as a painless lump. Metastasis to the regional lymph nodes and lungs is common. SS is proposed to be a result of a chromosomal translocation leading to the fusion of SYT and SSX genes. Standard treatment is tumor resection followed by adjuvant therapy. No study has compared the effects of different surgery and adjuvant therapy types on overall

APA, Harvard, Vancouver, ISO, and other styles

24

Aziz, S. A., M. A. Banday, and M. H. Mir. "Comparative efficacy of adjuvant chemoradiation versus chemotherapy in surgically resected adenocarcinoma of stomach." Journal of Clinical Oncology 27, no. 15_suppl (2009): e15639-e15639. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e15639.

Full text

Abstract:

e15639 Background: Outcome of carcinoma of stomach has not changed over the past decades and surgery remains the time tested primary modality of treatment. Attempts to improve survival have been strengthened by recent studies of adjuvant chemoradiation in these patients. The present study focuses to compare the efficacy of adjuvant chemoradiation Vs Chemotherapy alone in surgically resected adenocarcinoma of stomach. Methods: Over a two years period (Nov. 2006 to Oct 2008) 60 patients were enrolled and randomized to two arms with 30 patients in each arm. ArmA received adjuvant chemoradiation a

APA, Harvard, Vancouver, ISO, and other styles

25

McEachron, Jennifer, Lila Marshall, Nancy Zhou, et al. "Evaluation of Survival, Recurrence Patterns and Adjuvant Therapy in Surgically Staged High-Grade Endometrial Cancer with Retroperitoneal Metastases." Cancers 13, no. 9 (2021): 2052. http://dx.doi.org/10.3390/cancers13092052.

Full text

Abstract:

Background: We seek to evaluate the difference in recurrence patterns and survival among stage IIIC high-grade endometrial cancer treated with surgery followed by adjuvant chemotherapy alone, radiation therapy alone, or both (chemoradiation). Methods: A multicenter retrospective analysis of surgically staged IIIC HGEC receiving adjuvant therapy was conducted. HGEC was defined as grade 3 endometrioid adenocarcinoma, serous, clear cell and carcinosarcoma. Differences in the frequency of recurrence sites and treatment delays were identified using Pearson’s χ2 test. Progression-free survival (PFS)

APA, Harvard, Vancouver, ISO, and other styles

26

LEACH, S., C. BLANKE, and H. CHOY. "Pancreatic adenocarcinoma: Adjuvant, neoadjuvant, and intraoperative chemoradiation." Seminars in Radiation Oncology 7, no. 3 (1997): 24–32. http://dx.doi.org/10.1016/s1053-4296(97)80057-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Lee, Hyung-Sik. "Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: Adjuvant 5-FU/cisplatin and chemoradiation with capecitabine." World Journal of Gastroenterology 12, no. 4 (2006): 603. http://dx.doi.org/10.3748/wjg.v12.i4.603.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Saldhi, Prachi, Maya Mary Samuel, Peter T. Silberstein, and Jasleen Kaur Chaddha. "An analysis of treatment trends in sclerosing epithelioid fibrosarcoma." Journal of Clinical Oncology 42, no. 16_suppl (2024): e23547-e23547. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e23547.

Full text

Abstract:

e23547 Background: Sclerosing Epithelioid Fibrosarcoma (SEF) is a rare, malignant, soft tissue sarcoma found in the arms, legs, head, and neck. Histologically, SEF is characterized by a distinctive architecture composed of cords, nests, and/or sheets of uniform epithelioid cells. Previous studies have demonstrated that surgery with wide surgical margins is associated with superior outcomes in SEF patients. However, on account of the rare nature of SEF, insufficient research has been conducted on the association of treatment types with long-term survival. Using the National Cancer Database (NCD

APA, Harvard, Vancouver, ISO, and other styles

29

Joshi, Nikhil Purushottam, Supriya Mallick, Ajeet Gandhi, et al. "Pediatric glioblastoma: Results with adjuvant chemoradiation using temozolomide." Journal of Clinical Oncology 30, no. 15_suppl (2012): 2072. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.2072.

Full text

Abstract:

2072 Background: Paediatric glioblastoma patients are underrepresented in major trials for this disease. The value of concurrent and adjuvant temozolomide is not known in this subset of patients. Methods: We retrospectively analysed our database between 2004 and 2010. All patients were treated with maximally safe surgical resection. This was followed by a uniform treatment schedule of post-operative radiation according to RTOG guidelines with concurrent daily temozolomide at 75 mg per meter square. The radiation dose was 60 Gy in 30 fractions planned by 3 dimensional conformal radiotherapy. 4

APA, Harvard, Vancouver, ISO, and other styles

30

Schueneman, Aaron, Elizabeth Sugar, Jennifer Uram, et al. "Association of low total lymphocyte count with overall and disease-free survival in patients with resected pancreatic adenocarcinoma receiving the GM-CSF secreting pancreatic tumor vaccine in combination with adjuvant chemoradiation." Journal of Clinical Oncology 30, no. 15_suppl (2012): e14585-e14585. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14585.

Full text

Abstract:

e14585 Background: Pancreatectomy, though necessary for potential cure of pancreatic ductal carcinoma (PDA), can be associated with immune dysregulation. Low total lymphocyte count (TLC) has been found to be a poor prognostic indicator in several different tumor types. The goal of this study was to determine whether low TLC could affect response to therapy and survival in resected pancreatic cancer patients who received a GMCSF-secreting cell-based tumor vaccine (GVAX) in addition to standard adjuvant therapy. Methods: Retrospective analysis of 60 patients enrolled in a phase II trial evaluati

APA, Harvard, Vancouver, ISO, and other styles

31

Shalata, Walid, Hanna T. Frumin Edri, Ina Sarel, et al. "Is the Addition of Chemotherapy to Adjuvant Radiation in Merkel Cell Cancer Beneficial? Real-World Data with Long-Term Follow-Up." Cancers 17, no. 6 (2025): 945. https://doi.org/10.3390/cancers17060945.

Full text

Abstract:

Background: The role of adding chemotherapy to adjuvant radiation therapy in resectable Merkel cell carcinoma (MCC) remains controversial. Previous studies have shown conflicting results, and long-term outcome data are limited. Objectives: In this study, we aimed to evaluate the long-term survival outcomes of patients with resectable MCC treated with surgery followed by either radiation alone or combined chemoradiation. Methods: This retrospective multicenter cohort study analyzed 105 patients with resectable MCC treated between 1985 and 2023. Patients received either adjuvant radiation alone

APA, Harvard, Vancouver, ISO, and other styles

32

McEachron, Jennifer, Taryn Heyman, Lisa Shanahan, et al. "Multimodality adjuvant therapy and survival outcomes in stage I–IV uterine carcinosarcoma." International Journal of Gynecologic Cancer 30, no. 7 (2020): 1012–17. http://dx.doi.org/10.1136/ijgc-2020-001315.

Full text

Abstract:

ObjectivesUterine carcinosarcoma is a rare, aggressive form of uterine cancer with a high recurrence rate and poor survival at all stages. We sought to evaluate the outcomes of patients treated with chemotherapy versus a combination of chemotherapy and radiation (chemoradiation) to determine survival.MethodsA multicenter retrospective analysis of patients with stage I–IV carcinosarcoma was conducted from January 2000 to December 2017. Inclusion criteria were primary surgical management, defined as hysterectomy ± salpingo-oophorectomy, comprehensive surgical staging and/or tumor debulking, foll

APA, Harvard, Vancouver, ISO, and other styles

33

Huang, Nancy, Joseph Descallar, Wei Chua, et al. "Longitudinal Measurements of Inflammatory Indices During Treatment for Locally Advanced Rectal Cancer and Associations with Smoking, Ethnicity and Pathological Response." Radiation 5, no. 2 (2025): 15. https://doi.org/10.3390/radiation5020015.

Full text

Abstract:

This study explores the change in inflammatory markers over the course of neoadjuvant chemoradiation and adjuvant chemotherapy for LARC and assesses the association with clinicopathological factors at pre-specified time-points. We examined the trends of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP), carcinoembryonic antigen (CEA), fibrinogen, and albumin through multilevel modelling of 29 prospective LARC patients across six time-points: before neoadjuvant chemoradiation (T1), week 3 of chemoradiation (T2), post-chemoradiation (T3), post-sur

APA, Harvard, Vancouver, ISO, and other styles

34

Gong, Lei, Peng Tang, Hongjing Jiang, Xiaobin Shang, Hongdian Zhang, and Zhentao Yu. "PS02.123: LYMPH NODE METASTASIS STATUS AFTER DIFFERENT STRATEGIES OF NEO-ADJUVANT THERAPIES FOR THE ESOPHAGEAL SQUAMOUS CELLS CARCINOMAS." Diseases of the Esophagus 31, Supplement_1 (2018): 156. http://dx.doi.org/10.1093/dote/doy089.ps02.123.

Full text

Abstract:

Abstract Background Lymph node status is an essential prognostic factor for the long term survival of esophageal cancer patients. The impact of neo-adjuvant therpay on lymph node status remains unconcern, especially for squamous cells carcinomas. The study objectives were to retrospective analyzed the impact on the numbers and stations of metastasis of lymph nodes after the neo-adjuvant therapy. Methods Patients undergoing esophagectomy for thoracic esophageal squamous cell carcinoma at Tianjin Medical University Cancer Institute and Hospital from 2013 to 2017 were included in this study. Grou

APA, Harvard, Vancouver, ISO, and other styles

35

SM, Bindu, P. L. Rema, and Praveen Jacob Ninan. "Survival and Prognostic Factors in Patients with Glioblastoma Multiforme Receiving Radiation and Temozolomide – A Retrospective Study." Galore International Journal of Health Sciences and Research 6, no. 2 (2021): 69–78. http://dx.doi.org/10.52403/gijhsr.20210410.

Full text

Abstract:

Introduction: Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. The standard treatment is surgical excision, followed by concomitant chemoradiation and adjuvant treatment with temozolomide. The standard radiation dose is 60Gy/ 30 fractions 2 Gy per fraction. Temozolomide is an alkylating agent and dosage is 75mg/m2 concurrent with radiation and 150-200mg/m2 as adjuvant treatment. This study aims at studying the median survival and the various prognostic factors. Materials and Methods: This is a retrospective study conducted in Government Medical College, Alappuzha

APA, Harvard, Vancouver, ISO, and other styles

36

Suess, Christoph, Matthias Hipp, Tobias Ettl, et al. "Feasibility of Adjuvant Radiotherapy or Chemoradiation for Elderly Patients with Squamous Cell Carcinoma of the Head and Neck, and Its Correlation with Different Comorbidity Scores: A Retrospective Cohort Study." Cancers 17, no. 14 (2025): 2283. https://doi.org/10.3390/cancers17142283.

Full text

Abstract:

Background: With aging populations, the incidence of squamous cell carcinoma of the head and neck (SCCHN) among elderly patients is increasing. Although adjuvant radiotherapy or chemoradiation is a well-established component of multimodal treatment, elderly patients remain underrepresented in clinical trials. This study evaluates the feasibility of adjuvant radiotherapy and chemoradiation in patients over 70 years with SCCHN and explores the correlation between treatment feasibility and various comorbidity scores. Methods: We retrospectively analyzed patients over 70 years of age who received

APA, Harvard, Vancouver, ISO, and other styles

37

Schwandt, Anita, William C. Chen, Francesca Martra, Paolo Zola, Robert DeBernardo, and Charles A. Kunos. "Chemotherapy Plus Radiation in Advanced-Stage Endometrial Cancer." International Journal of Gynecologic Cancer 21, no. 9 (2011): 1622–27. http://dx.doi.org/10.1097/igc.0b013e31822b6594.

Full text

Abstract:

HypothesisWe hypothesize that adjuvant radiation and chemotherapy improve the clinical benefit from treatment of advanced-stage endometrial adenocarcinoma.MethodsWe conducted a retrospective review of 125 patient with stage III or IVA endometrial adenocarcinoma who received adjuvant chemotherapy (n = 60) or chemoradiation (n = 65). Primary end points were rate of clinical benefit (ie, the percentage of patients who were alive and disease-free for at least 6 months after the last day of adjuvant treatment) and progression-free and overall survival.ResultsThe addition of radiation to chemotherap

APA, Harvard, Vancouver, ISO, and other styles

38

Nasioudis, Dimitrios, Allison Grace Roy, Emily M. Ko, et al. "Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium." International Journal of Gynecologic Cancer 30, no. 8 (2020): 1089–94. http://dx.doi.org/10.1136/ijgc-2020-001379.

Full text

Abstract:

ObjectivesThe role of adjuvant treatment for early-stage uterine serous carcinoma is not defined. The goal of this study was to investigate the impact of adjuvant treatment on survival of patients with tumors confined to the endometrium.MethodsPatients diagnosed with stage I uterine serous carcinoma with no myometrial invasion between January 2004 and December 2015 who underwent hysterectomy with at least 10 lymph nodes removed were identified from the National Cancer Database. Adjuvant treatment patterns defined as receipt of chemotherapy and/or radiotherapy within 6 months from surgery were

APA, Harvard, Vancouver, ISO, and other styles

39

Smirnova, M. P., A. S. Khadzhimba, S. Ya Maksimov, A. A. Ilyin, and A. V. Pletneva. "Impact of adjuvant chemotherapy on relapse-free survival of patients with locally advanced cervical cancer." Tumors of female reproductive system 17, no. 4 (2022): 74–79. http://dx.doi.org/10.17650/1994-4098-2021-17-4-74-79.

Full text

Abstract:

Background. In the NCCN guidelines published in 2020, chemoradiation treatment with adjuvant chemotherapy for patients with stage FIGO III cervical cancer was considered counter-productive. Long-term outcomes of treatment for patients with locally advanced disease (IIIC) are still not satisfactory. The desire to change the current situation resulted in the studying of the effectiveness of adjuvant chemotherapy in cervical cancer patients with regional lymph nodes metastases.Objective: to evaluate the effectiveness of the combination of neoadjuvant chemoradiation plus adjuvant chemotherapy in p

APA, Harvard, Vancouver, ISO, and other styles

40

Polcz, Monica, Jesse Smith, and Philip Paty. "Evolving paradigms in locally advanced rectal cancer: Review of the non-operative approach and future directions." Acta chirurgica Iugoslavica 61, no. 2 (2014): 23–29. http://dx.doi.org/10.2298/aci1402023p.

Full text

Abstract:

The standard treatment of locally advanced rectal cancer in the United States is neoadjuvant chemoradiation, surgical resection with total mesorectal excision, and adjuvant chemotherapy. In recent years, a non-operative approach has been suggested for patients achieving a complete clinical response with chemoradiation alone to avoid the morbidity that accompanies radical excision. This approach is justified by the observation that a significant proportion of patients (15-40%) have achieved a pathological complete response by the time of surgery. We review the most recent literature to determin

APA, Harvard, Vancouver, ISO, and other styles

41

Baekey, John, Robert Brunault, Howard Safran, et al. "Complete neoadjuvant treatment for rectal cancer: A single institution experience." Journal of Clinical Oncology 38, no. 4_suppl (2020): 148. http://dx.doi.org/10.1200/jco.2020.38.4_suppl.148.

Full text

Abstract:

148 Background: Full dose adjuvant chemotherapy following preoperative chemoradiation and surgery is poorly tolerated in stage II and III rectal cancer. We reviewed our institution’s experience with complete neoadjuvant treatment for rectal cancer since publication of the BrUOG R-224 trial results. Methods: After obtaining IRB approval, Data on patients with stage II and III rectal cancer who underwent complete neoadjuvant therapy were collected.. Patients who were planned to receive 8 cycles of modified FOLFOX6, chemoradiation with capecitabine 825 mg/m2 twice daily and 50.4 Gy intensity-modu

APA, Harvard, Vancouver, ISO, and other styles

42

Goyal, Bhupesh K., Harkirat Singh, Krishan Kapur, Bhupinder S. Duggal, and Mattakarottu J. Jacob. "Value of PET-CT in Avoiding Multimodality Therapy in Operable Cervical Cancer." International Journal of Gynecologic Cancer 20, no. 6 (2010): 1041–45. http://dx.doi.org/10.1111/igc.0b013e3181dcadeb.

Full text

Abstract:

Background:Posttreatment morbidity of multimodality therapy is substantially higher than either radical surgery or chemoradiation alone. Preoperative prediction of positive nodes limits optimal selection of the primary treatment modality. Computed tomography (CT) and magnetic resonance imaging have been tried for nodal assessment with modest results. Positron emission tomography (PET) combined with CT seems to be promising in this regard. This clinicopathologic study assesses the value of PET-CT in predicting nodal metastasis and avoiding multimodality therapy.Materials and Methods:Eighty pati

APA, Harvard, Vancouver, ISO, and other styles

43

Serafini, Francesco M., Donald Sachs, Mark Bloomston, et al. "Location, not Staging, of Cholangiocarcinoma Determines the Role for Adjuvant Chemoradiation Therapy." American Surgeon 67, no. 9 (2001): 839–44. http://dx.doi.org/10.1177/000313480106700905.

Full text

Abstract:

The role of adjuvant chemoradiation therapy (CT/XRT) in the treatment of cholangiocarcinoma is controversial. We undertook this study to determine whether CT/XRT is appropriate after resection of cholangiocarcinomas. One hundred ninety-two patients with cholangiocarcinomas were treated from 1988 to 1999. After resection, patients were assigned a stage (TNM) and were stratified by location of the tumor as intrahepatic, perihilar, and distal tumors. Data are presented as mean ± standard deviation. Of 192 patients 92 (48%) underwent resections of cholangiocarcinomas. Thirty-four patients had live

APA, Harvard, Vancouver, ISO, and other styles

44

Kato, T., and T. Hirai. "Adjuvant Chemotherapy and Chemoradiation Therapy for Colorectal Cancer." Nippon Daicho Komonbyo Gakkai Zasshi 53, no. 10 (2000): 1000–1007. http://dx.doi.org/10.3862/jcoloproctology.53.1000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Thigpen, J. T. "Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma." Yearbook of Oncology 2012 (January 2012): 123–24. http://dx.doi.org/10.1016/j.yonc.2012.08.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Tang, Jie, Yanxiang Tang, Jun Yang, and Si Huang. "Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma." Gynecologic Oncology 125, no. 2 (2012): 297–302. http://dx.doi.org/10.1016/j.ygyno.2012.01.033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Loh, Jasmin, Steve MacLellan, Allan Okrainec, et al. "Gastric cancer recurrence after resection and adjuvant chemoradiation." Journal of Radiation Oncology 4, no. 1 (2015): 79–85. http://dx.doi.org/10.1007/s13566-015-0183-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Garofalo, Michael, Todd Flannery, and William Regine. "The case for adjuvant chemoradiation for pancreatic cancer." Best Practice & Research Clinical Gastroenterology 20, no. 2 (2006): 403–16. http://dx.doi.org/10.1016/j.bpg.2005.11.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Carr, John Alfred, Munther Ajlouni, Ira Wollner, Dominic Wong, and Vic Velanovich. "Adenocarcinoma of the Head of the Pancreas: Effects of Surgical and Nonsurgical Therapy on Survival—A Ten-Year Experience." American Surgeon 65, no. 12 (1999): 1143–49. http://dx.doi.org/10.1177/000313489906501210.

Full text

Abstract:

A retrospective analysis of all patients treated for adenocarcinoma of the head of the pancreas from 1989 to 1998 was performed. Excluded were cancers in the body and tail, cystic neoplasms, ampullary tumors, and cancers of the duodenum and bile ducts. One hundred forty-five patients were reviewed, and 43 patients underwent pancreaticoduodenectomy. Data collected included the stage, lymph node status, surgical margins, adjuvant therapies, and survival. Statistical analysis was performed with Cox's Proportional Hazards Analysis and Log-Rank Life Table Analysis. The surgical population had a 21

APA, Harvard, Vancouver, ISO, and other styles

50

Kumar, Abhishek, Manisha Palta, and Jingquan Jia. "Point/Counterpoint #1." Cancer Journal 30, no. 4 (2024): 251–55. http://dx.doi.org/10.1097/ppo.0000000000000735.

Full text

Abstract:

Abstract For decades, the standard neoadjuvant therapy regimen for locally advanced rectal cancer consisted of chemoradiation, surgical resection, and consideration of adjuvant systemic therapy. Additional data have emerged suggesting neoadjuvant systemic therapy as a reasonable alternative to chemoradiation in selected patients. In addition, a total neoadjuvant therapy approach integrating both chemotherapy and chemoradiation results in superior cancer outcomes and the potential for consideration of nonoperative management in patients with a clinical complete response. Despite a multitude of

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!